CLINICAL TRIALS PROFILE FOR AG-348
✉ Email this page to a colleague
Clinical Trials for AG-348
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02108106 ↗ | A Phase I Study of AG-348 in Healthy Volunteers | Completed | Agios Pharmaceuticals, Inc. | Phase 1 | This is a dose escalation study that will be conducted in healthy volunteers. Multiple cohorts of volunteers will receive ascending oral doses of AG-348 to evaluate the safety and tolerability of a single oral dose of AG-348, the pharmacokinetics (PK) of a single dose of AG-348, and the pharmacodynamic profile of AG-348 with specific biomarkers assessed in the blood. |
NCT02149966 ↗ | A Phase I Study of AG-348 in Healthy Volunteers | Completed | Agios Pharmaceuticals, Inc. | Phase 1 | This is a dose escalation study that will be conducted in healthy volunteers. Multiple cohorts of volunteers will receive ascending (increasingly higher) oral doses of AG-348 daily for 14 days to evaluate the safety and tolerability of multiple oral doses of AG-348, the pharmacokinetics (PK) of multiple doses of AG-348, and the pharmacodynamic profile of AG-348 with specific biomarkers assessed in the blood. |
NCT02476916 ↗ | A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency | Active, not recruiting | Agios Pharmaceuticals, Inc. | Phase 2 | Study AG348-C-003 is a multicenter study designed to evaluate the safety and efficacy of different dose levels of AG-348 (mitapivat) in participants with PK deficiency. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for AG-348
Condition Name
Clinical Trial Locations for AG-348
Trials by Country
Clinical Trial Progress for AG-348
Clinical Trial Phase
Clinical Trial Sponsors for AG-348
Sponsor Name